Cargando…

Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis

Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is hampered by the lack of specific markers defining these populations. Here we show...

Descripción completa

Detalles Bibliográficos
Autores principales: Jungwirth, Ute, van Weverwijk, Antoinette, Evans, Rachel J., Jenkins, Liam, Vicente, David, Alexander, John, Gao, Qiong, Haider, Syed, Iravani, Marjan, Isacke, Clare M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192501/
https://www.ncbi.nlm.nih.gov/pubmed/34112782
http://dx.doi.org/10.1038/s41467-021-23583-1
_version_ 1783706059383242752
author Jungwirth, Ute
van Weverwijk, Antoinette
Evans, Rachel J.
Jenkins, Liam
Vicente, David
Alexander, John
Gao, Qiong
Haider, Syed
Iravani, Marjan
Isacke, Clare M.
author_facet Jungwirth, Ute
van Weverwijk, Antoinette
Evans, Rachel J.
Jenkins, Liam
Vicente, David
Alexander, John
Gao, Qiong
Haider, Syed
Iravani, Marjan
Isacke, Clare M.
author_sort Jungwirth, Ute
collection PubMed
description Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is hampered by the lack of specific markers defining these populations. Here we show that genetic deletion of the Endo180 (MRC2) receptor, predominantly expressed by a population of matrix-remodelling CAFs, profoundly limits tumour growth and metastasis; effects that can be recapitulated in 3D co-culture assays. This impairment results from a CAF-intrinsic contractility defect and reduced CAF viability, which coupled with the lack of phenotype in the normal mouse, demonstrates that upregulated Endo180 expression by a specific, potentially targetable CAF subset is required to generate a supportive tumour microenvironment. Further, characterisation of a tumour subline selected via serial in vivo passage for its ability to overcome these stromal defects provides important insight into, how tumour cells adapt to a non-activated stroma in the early stages of metastatic colonisation.
format Online
Article
Text
id pubmed-8192501
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81925012021-07-01 Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis Jungwirth, Ute van Weverwijk, Antoinette Evans, Rachel J. Jenkins, Liam Vicente, David Alexander, John Gao, Qiong Haider, Syed Iravani, Marjan Isacke, Clare M. Nat Commun Article Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is hampered by the lack of specific markers defining these populations. Here we show that genetic deletion of the Endo180 (MRC2) receptor, predominantly expressed by a population of matrix-remodelling CAFs, profoundly limits tumour growth and metastasis; effects that can be recapitulated in 3D co-culture assays. This impairment results from a CAF-intrinsic contractility defect and reduced CAF viability, which coupled with the lack of phenotype in the normal mouse, demonstrates that upregulated Endo180 expression by a specific, potentially targetable CAF subset is required to generate a supportive tumour microenvironment. Further, characterisation of a tumour subline selected via serial in vivo passage for its ability to overcome these stromal defects provides important insight into, how tumour cells adapt to a non-activated stroma in the early stages of metastatic colonisation. Nature Publishing Group UK 2021-06-10 /pmc/articles/PMC8192501/ /pubmed/34112782 http://dx.doi.org/10.1038/s41467-021-23583-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jungwirth, Ute
van Weverwijk, Antoinette
Evans, Rachel J.
Jenkins, Liam
Vicente, David
Alexander, John
Gao, Qiong
Haider, Syed
Iravani, Marjan
Isacke, Clare M.
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
title Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
title_full Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
title_fullStr Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
title_full_unstemmed Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
title_short Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
title_sort impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192501/
https://www.ncbi.nlm.nih.gov/pubmed/34112782
http://dx.doi.org/10.1038/s41467-021-23583-1
work_keys_str_mv AT jungwirthute impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT vanweverwijkantoinette impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT evansrachelj impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT jenkinsliam impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT vicentedavid impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT alexanderjohn impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT gaoqiong impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT haidersyed impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT iravanimarjan impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis
AT isackeclarem impairmentofadistinctcancerassociatedfibroblastpopulationlimitstumourgrowthandmetastasis